Approval of Abilify Inj makes confrontation against Janssen’s Invega
In the long-acting injectable(LAI) market for schizophrenia, which has been monopolized by Janssen with Invega Sustenna Inj, Korea Otsuka Pharmaceuticals’ Abilify Inj formed the 2-way competition as acquiring approval.
As having high potential from excellent drug compliance compared to existing ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
